Bank of America has revised its price target for Phibro Animal Health (PAHC, Financial), lowering it from $22 to $18 while maintaining an Underperform rating on the stock. As the company approaches its first-quarter earnings announcement, analysts highlight concerns regarding the overall sentiment within the animal health sector, which is perceived as largely negative.
The firm indicates that both broader market conditions and specific challenges faced by the company contribute to this outlook. In this context, there appear to be limited immediate opportunities that might enhance estimates for Phibro Animal Health. Although improved foreign exchange rates could offer some relief, the expectation is that the stock will likely hover around its current value in the near term.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Phibro Animal Health Corp (PAHC, Financial) is $21.00 with a high estimate of $22.00 and a low estimate of $20.00. The average target implies an upside of 28.28% from the current price of $16.37. More detailed estimate data can be found on the Phibro Animal Health Corp (PAHC) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Phibro Animal Health Corp's (PAHC, Financial) average brokerage recommendation is currently 3.3, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Phibro Animal Health Corp (PAHC, Financial) in one year is $21.98, suggesting a upside of 34.27% from the current price of $16.37. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Phibro Animal Health Corp (PAHC) Summary page.
